Orbcel-C

Phase 2Cell therapy

UUniversity of Birmingham

Orbcel-C is one of 3 biologic programs targeting Mesenchymal Stromal Cells. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Mesenchymal Stromal CellsActive, not recruiting

Mesenchymal Stromal CellsPhase 2

Active, not recruiting

Competition

Competitive Landscape

2 competitors in Mesenchymal Stromal Cells

#DrugCompanyPhaseTrials

Allo-APZ2-CVU

RRHEACELL GmbH & Co. KG

Phase 3

2 2

Orbcel-C

UUniversity of Birmingham

Phase 2

1 3

Imsc

RRuijin Hospital

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Mesenchymal Stromal Cells1 trial

Selected Mesenchymal Stromal Cells to Reduce Inflammation in Patients With PSC and AIH

Active, not recruiting·UUniversity of Birmingham·Phase 1/2·NCT02997878·18 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Orbcel-C. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Orbcel-C compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Orbcel-C. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — University of Birmingham company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Cell therapy[2]
Highest Phase: Phase 2[1]
Company: UUniversity of Birmingham

Orbcel-C

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Mesenchymal Stromal Cells1 trial

References

Drug Info

Quick Facts

Related News